<DOC>
	<DOCNO>NCT01450098</DOCNO>
	<brief_summary>The purpose study evaluate safety single dose LY2484595 compare amount LY2484595 blood healthy non-Asian subject , Chinese subject first generation Japanese subject receive single oral dose LY2484595 fast state , eat low-fat meal eat high-fat meal .</brief_summary>
	<brief_title>A Study LY2484595 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Propyl Gallate</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination . For Cohort B , firstgeneration Japanese subject define one Japanese bear Japan whose parent grandparents Japanese born Japan . A firstgeneration Chinese subject define one Chinese bear China ( mainland Taiwan ) whose parent grandparents Chinese born China Female subject childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Women intact uterus deem postmenopausal least age 45 , cessation menses least 1 year , take hormone oral contraceptive ( include estrogen hormone replacement therapy ) past 12 month Are body mass index ( BMI ) 18.5 29.0 kg/m^2 , inclusive Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Acceptable blood pressure ( BP ) heart rate supine stand position determine investigator ( systolic BP le equal 140 mm Hg , diastolic BP le equal 90 mm Hg ) . A single repeat BP measurement may do discretion investigator Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Eli Lilly Company ( hereafter , Lilly ) ethical review board ( ERB ) govern site Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device , offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2484595 related compound Are person previously complete withdrawn study Have abnormality 12lead electrocardiogram ( ECG ) ( include limit Bazett 's correct QT [ QTcB ] interval &gt; 450 msec men &gt; 470 msec woman ) , opinion investigator , increase risk associate participate study Have history within last 2 year presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic , neurologic disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Show evidence significant active neuropsychiatric disease Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Intend use actually use overthecounter prescription medication dietary supplement within 14 day prior dose ( acetaminophen permissible asneeded basis , le 3 gram per day le 7 day ) Have donate blood 500 mL within last month Have average alcohol intake exceeds 14 unit per week , unwilling stop alcohol consumption 48 hour prior inpatient confinement Clinical Research Unit ( CRU ) ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Use herbal supplement , grapefruit juice , grapefruit , Seville orange juice , Seville oranges , starfruit within 7 day prior study dose Smoke 10 cigarette per day currently unwilling abide CRU guideline Are unwilling refrain daily consumption real licorice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>